Patients interested in learning more about JUVÉDERM ® VOLUMA ® XC for temple hollowing are encouraged to enroll in Allē, the Allergan Aesthetics loyalty rewards program. In serving more than seven ...

Both treatments may cause mild, temporary side effects such as swelling or bruising. Some of the more serious side effects include infection, stroke, and blindness. Radiesse and Juvéderm are ...

IRVINE, Calif., Aug. 1, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the first ever JUVÉDERM ® Day on Wednesday, August 16, 2023. The celebration recognizes the ...

Juvéderm and Restylane are two types of dermal fillers used for the treatment of wrinkles. Both injections use a gel made with hyaluronic acid to plump up the skin. These are noninvasive procedures.

Allergan Announces FDA Approval of Label Extensions for JUVEDERM Ultra and JUVEDERM Ultra Plus IRVINE, Calif. -- Allergan, Inc., the maker of BOTOX® Cosmetic (Botulinum Toxin Type A), today announced ...

Perioral Rhytids Allergan announced that the Food and Drug Administration (FDA) has approved Juvederm Volbella XC for use in lip augmentation and for correction of perioral rhytids (referred to as ...

IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc., (NYSE:AGN) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVÉDERM VOLUMA™ XC, the ...

Please provide your email address to receive an email when new articles are posted on . The FDA announced it has updated its dermal fillers website to include a ...

JUVÉDERM® VOLUX™ XC IS THE FIRST AND ONLY HYALURONIC ACID (HA) FILLER TO RECEIVE U.S. FDA APPROVAL FOR IMPROVING JAWLINE DEFINITION IRVINE, Calif., Aug. 3, 2022 /PRNewswire/ -- Today, Allergan ...

IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc. (NYSE:AGN), the maker of BOTOX ® Cosmetic (Botulinum Toxin Type A), today announced nationwide availability of its ‘next-generation’ hyaluronic acid ...

First and Only Filler Approved for Lip Augmentation that Lasts Up to One Year DUBLIN, Oct. 1, 2015 /PRNewswire/ -- Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, today announced ...